Canine Distemper + Adenovirus Type 2 + Parainfluenza + Parvovirus Vaccine

Verify with FDA CVM →

79 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
79
Total Reports
8
Deaths Reported
1010.0%
Death Rate

Active Ingredients

Canine Distemper + Adenovirus Type 2 + Parainfluenza + Parvovirus Vaccine

Administration Routes

UnknownParenteralSubcutaneous

Species Affected

Dog 79

Most Affected Breeds

Retriever - Labrador 13
Retriever - Golden 7
Chihuahua 6
Crossbred Canine/dog 5
Beagle 4
Terrier - Jack Russell 3
Pit Bull 2
Retriever (unspecified) 2
Terrier - Yorkshire 2
Shepherd Dog - German 2

Most Reported Reactions

Vomiting 18
Lethargy (see also Central nervous system depression in 'Neurological') 13
Diarrhoea 12
Seizure NOS 9
Other abnormal test result NOS 8
Lack of efficacy (endoparasite) - heartworm 7
Lack of efficacy - NOS 6
Behavioural disorder NOS 5
Monocytosis 5
Lack of efficacy (virus) - parvovirus (including feline panleukopenia) 5
Death by euthanasia 4
Death 4

Outcome Breakdown

Outcome Unknown
29 (36.7%)
Recovered/Normal
28 (35.4%)
Ongoing
13 (16.5%)
Euthanized
4 (5.1%)
Died
4 (5.1%)
Recovered with Sequela
1 (1.3%)

Data Summary

Metric Value
Total adverse event reports 79
Reports involving death 8
Case-fatality rate (reported events) 1010.0%
Distinct species in reports 1
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Canine Distemper + Adenovirus Type 2 + Parainfluenza + Parvovirus Vaccine Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 79 adverse event reports referencing Canine Distemper + Adenovirus Type 2 + Parainfluenza + Parvovirus Vaccine, including 8 reports in which the animal died — a 1010.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Canine Distemper + Adenovirus Type 2 + Parainfluenza + Parvovirus Vaccine. Reported administration routes include Unknown, Parenteral, Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Canine Distemper + Adenovirus Type 2 + Parainfluenza + Parvovirus Vaccine reports are Dog (79 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (13), Retriever - Golden (7), Chihuahua (6) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Canine Distemper + Adenovirus Type 2 + Parainfluenza + Parvovirus Vaccine are Vomiting (18), Lethargy (see also Central nervous system depression in 'Neurological') (13), Diarrhoea (12), Seizure NOS (9). Of the 79 reports with a coded outcome, Outcome Unknown is the leading category at 36.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Canine Distemper + Adenovirus Type 2 + Parainfluenza + Parvovirus Vaccine.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial